Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epallolitovorizumab plus cisplatin + paclitaxel as neoadjuvant therapy for locally advanced cervical cancer
ChiCTR2500107314Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epallolitovorizumab in Cervical Cancer (CC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Objective Response Rate and Overall Survival. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
epallolitovorizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500107314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107314.